Radiation therapy for returning or limited-spread prostate cancer
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This trial compares two types of radiation therapy for prostate cancer that has come back or spread to a few places after surgery. The goal is to see which radiation schedule works better with fewer side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have had surgery to remove your prostate.
- Your PSA (prostate-specific antigen) level after surgery should be between 0.1 and 2.0 ng/mL.
- You can have up to 5 spots where the cancer has spread (oligometastatic disease).
- You must be well enough to do your daily activities (ECOG score 0, 1, or 2).
- You cannot have had radiation or chemotherapy for prostate cancer before.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether some men with high-risk prostate cancer can safely receive less hormone therapy when combined with radiation. It aims to reduce side effects while still effectively treating the cancer.
This study is testing whether using focused radiation beams (SBRT) right away or later, along with hormone therapy, can help control prostate cancer that has returned in a few spots outside the pelvis. The goal is to find the best timing for combining radiation and hormone treatment.
This trial tests whether adding targeted radiation guided by a PET scan (along with hormone therapy) can improve outcomes for prostate cancer that has come back after surgery. The PET scan helps doctors look for spots outside the usual radiation area so treatment can be tailored.
This trial tests whether a shorter course of radiation works as well as the usual longer course for people with high-risk prostate cancer. The goal is to keep cancer control while possibly reducing treatment time and inconvenience.
This trial tests a powerful radioactive drug (either alpha or beta) combined with precise radiation to treat prostate cancer that has come back in a few spots outside the prostate. It may help men whose cancer is still hormone-sensitive and has not spread widely.
This trial tests a precise radiation technique that adapts to your body's daily changes. It may offer better outcomes for men with prostate cancer that hasn't spread outside the pelvic area.
Hear when a new Biochemically Recurrent Prostate Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.